Cargando…

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

INTRODUCTION: Very few studies have investigated whether the time elapsed between surgical resection and tissue fixation or the difference between core-cut and excision biopsies impact on immunohistochemically measured biomarkers, including phosphorylated proteins in primary breast cancer. The aim o...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinhel, Isabel F, MacNeill, Fiona A, Hills, Margaret J, Salter, Janine, Detre, Simone, A'Hern, Roger, Nerurkar, Ashutosh, Osin, Peter, Smith, Ian E, Dowsett, Mitch
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096968/
https://www.ncbi.nlm.nih.gov/pubmed/20920193
http://dx.doi.org/10.1186/bcr2719
_version_ 1782203772665069568
author Pinhel, Isabel F
MacNeill, Fiona A
Hills, Margaret J
Salter, Janine
Detre, Simone
A'Hern, Roger
Nerurkar, Ashutosh
Osin, Peter
Smith, Ian E
Dowsett, Mitch
author_facet Pinhel, Isabel F
MacNeill, Fiona A
Hills, Margaret J
Salter, Janine
Detre, Simone
A'Hern, Roger
Nerurkar, Ashutosh
Osin, Peter
Smith, Ian E
Dowsett, Mitch
author_sort Pinhel, Isabel F
collection PubMed
description INTRODUCTION: Very few studies have investigated whether the time elapsed between surgical resection and tissue fixation or the difference between core-cut and excision biopsies impact on immunohistochemically measured biomarkers, including phosphorylated proteins in primary breast cancer. The aim of this study was to characterise the differences in immunoreactivity of common biomarkers that may occur (1) as a result of tissue handling at surgery and (2) between core-cuts and resected tumours. METHODS: Core-cuts taken from surgical breast cancer specimens immediately after resection (sample A) and after routine X-ray of the excised tumour (sample B) were formalin-fixed and paraffin-embedded and compared with the routinely fixed resection specimen (sample C). The variation in immunohistochemical expression of Ki67, oestrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor 2 (HER2), p-Akt and p-Erk1/2 were investigated. RESULTS: Twenty-one tissue sets with adequate tumour were available. Median time between collection of core-cuts A and B was 30 minutes (range, 20 to 80 minutes). None of the markers showed significant differences between samples A and B. Similarly, Ki67, ER, PgR and HER2 did not differ significantly between core-cuts and main resection specimen, although there was a trend for lower resection values for ER (P = 0.06). However, p-Akt and p-Erk1/2 were markedly lower in resections than core-cuts (median, 27 versus 101 and 69 versus 193, respectively; both P < 0.0001 [two-sided]). This difference was significantly greater in mastectomy than in lumpectomy specimens for p-Erk1/2 (P = 0.01). CONCLUSIONS: The delay in fixation in core-cuts taken after postoperative X-ray of resection specimens has no significant impact on expression of Ki67, ER, PgR, HER2, p-Akt or p-Erk1/2. However, extreme loss of phospho-staining can occur during routine fixation of resection specimens. These differences are likely attributable to suboptimal fixation and may have major repercussions for clinical research involving these markers.
format Text
id pubmed-3096968
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30969682011-05-18 Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer Pinhel, Isabel F MacNeill, Fiona A Hills, Margaret J Salter, Janine Detre, Simone A'Hern, Roger Nerurkar, Ashutosh Osin, Peter Smith, Ian E Dowsett, Mitch Breast Cancer Res Research Article INTRODUCTION: Very few studies have investigated whether the time elapsed between surgical resection and tissue fixation or the difference between core-cut and excision biopsies impact on immunohistochemically measured biomarkers, including phosphorylated proteins in primary breast cancer. The aim of this study was to characterise the differences in immunoreactivity of common biomarkers that may occur (1) as a result of tissue handling at surgery and (2) between core-cuts and resected tumours. METHODS: Core-cuts taken from surgical breast cancer specimens immediately after resection (sample A) and after routine X-ray of the excised tumour (sample B) were formalin-fixed and paraffin-embedded and compared with the routinely fixed resection specimen (sample C). The variation in immunohistochemical expression of Ki67, oestrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor 2 (HER2), p-Akt and p-Erk1/2 were investigated. RESULTS: Twenty-one tissue sets with adequate tumour were available. Median time between collection of core-cuts A and B was 30 minutes (range, 20 to 80 minutes). None of the markers showed significant differences between samples A and B. Similarly, Ki67, ER, PgR and HER2 did not differ significantly between core-cuts and main resection specimen, although there was a trend for lower resection values for ER (P = 0.06). However, p-Akt and p-Erk1/2 were markedly lower in resections than core-cuts (median, 27 versus 101 and 69 versus 193, respectively; both P < 0.0001 [two-sided]). This difference was significantly greater in mastectomy than in lumpectomy specimens for p-Erk1/2 (P = 0.01). CONCLUSIONS: The delay in fixation in core-cuts taken after postoperative X-ray of resection specimens has no significant impact on expression of Ki67, ER, PgR, HER2, p-Akt or p-Erk1/2. However, extreme loss of phospho-staining can occur during routine fixation of resection specimens. These differences are likely attributable to suboptimal fixation and may have major repercussions for clinical research involving these markers. BioMed Central 2010 2010-09-28 /pmc/articles/PMC3096968/ /pubmed/20920193 http://dx.doi.org/10.1186/bcr2719 Text en Copyright ©2010 Pinhel et al.; licensee BioMed Central Ltd http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Pinhel, Isabel F
MacNeill, Fiona A
Hills, Margaret J
Salter, Janine
Detre, Simone
A'Hern, Roger
Nerurkar, Ashutosh
Osin, Peter
Smith, Ian E
Dowsett, Mitch
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
title Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
title_full Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
title_fullStr Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
title_full_unstemmed Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
title_short Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer
title_sort extreme loss of immunoreactive p-akt and p-erk1/2 during routine fixation of primary breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096968/
https://www.ncbi.nlm.nih.gov/pubmed/20920193
http://dx.doi.org/10.1186/bcr2719
work_keys_str_mv AT pinhelisabelf extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer
AT macneillfionaa extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer
AT hillsmargaretj extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer
AT salterjanine extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer
AT detresimone extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer
AT ahernroger extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer
AT nerurkarashutosh extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer
AT osinpeter extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer
AT smithiane extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer
AT dowsettmitch extremelossofimmunoreactivepaktandperk12duringroutinefixationofprimarybreastcancer